Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs 10X Genomics Inc — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.74 (market cap $3.14B), while 10X Genomics Inc trades at $83.55 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 3.2× Invesco S&P 500 High Div Low Volatility ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and 10X Genomics Inc for 92 Days on average.
| SPHD | TXG | |
|---|---|---|
Market Cap | $3.14B | $10.07B |
Volume | 1,461,349 | 5,657,286 |
52-Week High | $53.55 | $97.74 |
52-Week Low | $46.96 | $11.48 |
Typical Hold Time | 125 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.72 with a 1.1% daily gain, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF's monthly dividend structure provides consistent income, though recent analysis highlights underperformance compared to peers like SCHD over the past decade. Key support sits at $47 with resistance at $49.
The outlook remains cautious given bearish technical signals and competitive pressure from higher-performing dividend ETFs. While monthly dividends appeal to income-focused investors, SPHD's lack of quality screening exposes it to yield traps. Near-term performance depends on market volatility and dividend sustainability.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
